Review Paper
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Olivia Dean, Frank Giorlando and Michael Berk
J Psychiatry Neurosci March 01, 2011 36 (2) 78-86; DOI: https://doi.org/10.1503/jpn.100057
Olivia Dean
Dean, Berk — Mental Health Research Institute, Parkville; Dean, Giorlando, Berk — Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong; Berk — Youth Health Orygen Research Centre, Parkville, and the School of Medicine, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University, Geelong, Victoria, Australia
BSc, PhDFrank Giorlando
Dean, Berk — Mental Health Research Institute, Parkville; Dean, Giorlando, Berk — Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong; Berk — Youth Health Orygen Research Centre, Parkville, and the School of Medicine, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University, Geelong, Victoria, Australia
MBBS, BMedScMichael Berk
Dean, Berk — Mental Health Research Institute, Parkville; Dean, Giorlando, Berk — Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong; Berk — Youth Health Orygen Research Centre, Parkville, and the School of Medicine, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University, Geelong, Victoria, Australia
MBBCh, MMed(Psych), PhD![Loading Loading](https://www.jpn.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Olivia Dean, Frank Giorlando, Michael Berk
J Psychiatry Neurosci Mar 2011, 36 (2) 78-86; DOI: 10.1503/jpn.100057
Related Articles
- No related articles found.
Cited By...
- A Targeted, Low-Throughput Compound Screen in a Drosophila Model of Neurofibromatosis Type 1 Identifies Simvastatin and BMS-204352 as Potential Therapies for Autism Spectrum Disorder (ASD)
- NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos
- Vitamin D and Depression: Cellular and Regulatory Mechanisms
- Acetylcysteine for treatment of autism spectrum disorder symptoms
- Oral acetylcysteine for neuropsychiatric disorders
- N-Acetylcysteine- and MK-801-Induced Changes in Glutamate Levels Do Not Affect In Vivo Binding of Metabotropic Glutamate 5 Receptor Radioligand 11C-ABP688 in Rat Brain